Virtual clinical trials now being used to fast-track drug development during coronavirus crisis

Other prominent start-ups in the space include Science 37, a full-service virtual trial platform, and Unlearn.AI, a service that creates digital twins of patients to expand data sets. In April, Unlearn.A1 received $12 million in Series A financing led by 8VC.

The U.S. Food and Drug Administration also helped clear the path to virtual trials in March by issuing guidelines for clinical studies during the pandemic that included “evaluating alternative methods for assessments, like phone contacts or virtual visits, and offering additional safety monitoring for those trial participants who may no longer have access to investigational product or the investigational site.”

Enter your email address to download paper.

Click the link to begin download.
Oops! Something went wrong while submitting the form.
Publications

Modeling Disease Progression in Mild Cognitive Impairment and Alzheimer's Disease with Digital Twins

Publications

Bayesian prognostic covariate adjustment

Publications

Using Digital Twins to Decrease Enrollment and Increase Statistical Power in Alzheimer's Disease Trials (CTAD 2020)

We showed that digital twins could reduce the number of control subjects required in the analysis to achieve equivalent results to an analysis of the actual subjects.
Our novel method - Bayesian prognostic covariate adjustment - is a Bayesian analysis that draws on the strengths of the prognostic model approach.
Here, we have demonstrated that a particular type of generative model (i.e., CRBMs) can be used to accurately model disease progression for patients with MCI or AD.